26 reports of this reaction
2.5% of all PHENAZOPYRIDINE HYDROCHLORIDE reports
#6 most reported adverse reaction
SULPHAEMOGLOBINAEMIA is the #6 most commonly reported adverse reaction for PHENAZOPYRIDINE HYDROCHLORIDE, manufactured by i-Health, Inc.. There are 26 FDA adverse event reports linking PHENAZOPYRIDINE HYDROCHLORIDE to SULPHAEMOGLOBINAEMIA. This represents approximately 2.5% of all 1,029 adverse event reports for this drug.
Patients taking PHENAZOPYRIDINE HYDROCHLORIDE who experience sulphaemoglobinaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SULPHAEMOGLOBINAEMIA is a less commonly reported adverse event for PHENAZOPYRIDINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to sulphaemoglobinaemia, the following adverse reactions have been reported for PHENAZOPYRIDINE HYDROCHLORIDE:
SULPHAEMOGLOBINAEMIA has been reported as an adverse event in 26 FDA reports for PHENAZOPYRIDINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SULPHAEMOGLOBINAEMIA accounts for approximately 2.5% of all adverse event reports for PHENAZOPYRIDINE HYDROCHLORIDE, making it a notable side effect.
If you experience sulphaemoglobinaemia while taking PHENAZOPYRIDINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.